Statins and hemoperfusion improve 28-day survival in septic shock patients

Tsukasa Nakamura, Eiichi Sato, Nobuharu Fujiwara, Yasuhiro Kawagoe, Sayaka Maeda, Hiroyoshi Inoue, Sho Ichi Yamagishi

Research output: Contribution to journalArticle

Abstract

Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

Original languageEnglish
Pages (from-to)475-480
Number of pages6
JournalCentral European Journal of Medicine
Volume7
Issue number4
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Hemoperfusion
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Septic Shock
Polymyxin B
Survival
Endotoxins
HDL Cholesterol
Physical Examination
Albumins
Creatinine
Sepsis
Anti-Inflammatory Agents
History
Regression Analysis
Inflammation
Mortality

Keywords

  • Inflammation
  • PMX-F
  • Septic shock
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Maeda, S., Inoue, H., & Yamagishi, S. I. (2012). Statins and hemoperfusion improve 28-day survival in septic shock patients. Central European Journal of Medicine, 7(4), 475-480. https://doi.org/10.2478/s11536-011-0169-z

Statins and hemoperfusion improve 28-day survival in septic shock patients. / Nakamura, Tsukasa; Sato, Eiichi; Fujiwara, Nobuharu; Kawagoe, Yasuhiro; Maeda, Sayaka; Inoue, Hiroyoshi; Yamagishi, Sho Ichi.

In: Central European Journal of Medicine, Vol. 7, No. 4, 08.2012, p. 475-480.

Research output: Contribution to journalArticle

Nakamura, T, Sato, E, Fujiwara, N, Kawagoe, Y, Maeda, S, Inoue, H & Yamagishi, SI 2012, 'Statins and hemoperfusion improve 28-day survival in septic shock patients', Central European Journal of Medicine, vol. 7, no. 4, pp. 475-480. https://doi.org/10.2478/s11536-011-0169-z
Nakamura, Tsukasa ; Sato, Eiichi ; Fujiwara, Nobuharu ; Kawagoe, Yasuhiro ; Maeda, Sayaka ; Inoue, Hiroyoshi ; Yamagishi, Sho Ichi. / Statins and hemoperfusion improve 28-day survival in septic shock patients. In: Central European Journal of Medicine. 2012 ; Vol. 7, No. 4. pp. 475-480.
@article{514ca076be4a47a3995b9ce835ac7a2a,
title = "Statins and hemoperfusion improve 28-day survival in septic shock patients",
abstract = "Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.",
keywords = "Inflammation, PMX-F, Septic shock, Statins",
author = "Tsukasa Nakamura and Eiichi Sato and Nobuharu Fujiwara and Yasuhiro Kawagoe and Sayaka Maeda and Hiroyoshi Inoue and Yamagishi, {Sho Ichi}",
year = "2012",
month = "8",
doi = "10.2478/s11536-011-0169-z",
language = "English",
volume = "7",
pages = "475--480",
journal = "Central European Journal of Medicine",
issn = "1895-1058",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Statins and hemoperfusion improve 28-day survival in septic shock patients

AU - Nakamura, Tsukasa

AU - Sato, Eiichi

AU - Fujiwara, Nobuharu

AU - Kawagoe, Yasuhiro

AU - Maeda, Sayaka

AU - Inoue, Hiroyoshi

AU - Yamagishi, Sho Ichi

PY - 2012/8

Y1 - 2012/8

N2 - Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

AB - Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

KW - Inflammation

KW - PMX-F

KW - Septic shock

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84865713331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865713331&partnerID=8YFLogxK

U2 - 10.2478/s11536-011-0169-z

DO - 10.2478/s11536-011-0169-z

M3 - Article

AN - SCOPUS:84865713331

VL - 7

SP - 475

EP - 480

JO - Central European Journal of Medicine

JF - Central European Journal of Medicine

SN - 1895-1058

IS - 4

ER -